Last reviewed · How we verify
NCT03239249: IKO
The Cluster-randomized Evaluation of the IKO-model
NA trial testing IKO-model in School Drop Out Prevention in 7,678 participants. Completed in 1 December 2021.
1 December 2021
Quick facts
| Lead sponsor | Oslo Metropolitan University |
|---|---|
| Phase | NA |
| Status | Completed |
| Study type | INTERVENTIONAL |
| Allocation | randomized |
| Design | parallel |
| Masking | single |
| Primary purpose | treatment |
| Enrollment | 7,678 |
| Start date | 1 March 2016 |
| Primary completion | 1 December 2021 |
| Estimated completion | 1 December 2021 |
| Sites | 42 locations across Norway |
Drugs / interventions tested
- IKO-model
- Treatment as usual
Conditions studied
- School Drop Out Prevention — all drugs for School Drop Out Prevention →
Sponsor
Oslo Metropolitan University
Who can join
Adults 15 to 16, any sex, with School Drop Out Prevention. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
The aim of this study is to analyze whether and how a systemic school-level approach to dropout prevention (the IKO-model), increase the completion rate from upper secondary school. The hypothesis is that schools that implement the model (i.e. randomized to the experimental group), will reduce the amount of students in risk of dropout, compared to their counterparts in schools randomized to the control group. The main expected outcomes in the study are; 1) increased amounts of students in upper secondary education completing their education within the three-year standard length of education, 2) decreased amounts of school-drop out, and 3) reduced values in mediating variables, such as low achievement, course failures, lack of attendance and lack of school-motivation and -effort. Accordingly, implementation quality and fidelity to the model will be assessed, both with quantitative (survey) and qualitative (interviews and observation) data. A total of five counties and 42 upper secondary schools participate in the evaluation project. One of the counties (Akershus County) have developed and piloted the model and function as a mentor in the other four counties (Oppland, Hedmark, Nord-Trøndelag and Hamar). While 20 schools have been randomized to the experimental group, 22 schools have been randomized to the control group. Schools randomized to the control group will work as earlier with school dropout.
Publications & conference data
No peer-reviewed publications indexed yet for this trial. Completed trials usually publish results within 12-18 months.
Verify or expand the search:
- PubMed search for NCT03239249
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other Oslo Metropolitan University trials
Trials by the same sponsor.
- NCT06578260 — Support Groups - a Model for Social Inclusion and Reduction of Bullying in School · NA · recruiting
- NCT05784324 — COMPRESSED - A Longitudinal Study of Compressed Work Schedules Within the Health, Care and Welfare Services · not yet recruiting
- NCT05895604 — The Mother in Norway Study · NA · recruiting
- NCT06117098 — Mobile App for Risk Reduction of Type 2 Diabetes · NA · unknown
- NCT05697120 — Long-term Effects of Individualized Follow-up With an App for One Year · completed
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT03239249 (US National Library of Medicine, public domain)
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by Oslo Metropolitan University
- Last refreshed: 28 September 2022
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT03239249.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing